Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome

Ferring Pharmaceuticals4 enrolled

Overview

Assessment of long-term effectiveness of ZOMACTON in treatment of Growth Hormone Deficiency or growth retardation due to Ullrich-Turner Syndrome and assessment of compliance and adherence, optionally with the aid of an electronic app or patient diary.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Growth Disorders

Interventions

ZomactonDRUG

Injection

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pediatric patients (\< 18 years) with growth hormone deficiency or growth retardation due to Ullrich-Turner-Syndrome * Patients already receiving or who have been prescribed Zomacton® de novo according to its German label; the decision to prescribe Zomacton® was made independently from participation and prior to enrollment in this study. * Patient and their parents (or legal representatives) who are willing and able to provide signed informed consent for use of their personal data. Exclusion Criteria: * Participation in an interventional clinical study within the last 30 days prior to baseline visit or during the follow-up period

Locations (1)

Klinik fuer Allgemeine Paediatrie der Christian-Albrechts-Universitaet zu Kiel (there might be other sites in this country)

Kiel, Germany

Outcomes

Primary Outcomes

Linear growth (change in height)

Change in height defined as the change of the standard deviation score of body height vs. baseline

Time frame: Over the first 12 months (month 0, 3, 6, 9 and 12)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.